| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2108 | 2018 |
| Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update M Omata, AL Cheng, N Kokudo, M Kudo, JM Lee, J Jia, R Tateishi, ... Hepatology international 11, 317-370, 2017 | 1901 | 2017 |
| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1439 | 2020 |
| JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan M Kudo, O Matsui, N Izumi, H Iijima, M Kadoya, Y Imai, T Okusaka, ... Liver cancer 3 (3-4), 458-468, 2014 | 625 | 2014 |
| Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update M Kudo, Y Kawamura, K Hasegawa, R Tateishi, K Kariyama, S Shiina, ... Liver cancer 10 (3), 181-223, 2021 | 384 | 2021 |
| Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update M Kudo, O Matsui, N Izumi, M Kadoya, T Okusaka, S Miyayama, ... Oncology 87 (Suppl. 1), 22-31, 2014 | 263 | 2014 |
| Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a … M Kudo, K Ueshima, O Yokosuka, S Ogasawara, S Obi, N Izumi, H Aikata, ... The lancet Gastroenterology & hepatology 3 (6), 424-432, 2018 | 260 | 2018 |
| Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, VV Breder, ... Journal of Clinical Oncology 37 (15_suppl), 4004-4004, 2019 | 211 | 2019 |
| KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... J Clin Oncol 38 (3), 193-202, 2020 | 187 | 2020 |
| Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization S Ogasawara, T Chiba, Y Ooka, N Kanogawa, T Motoyama, E Suzuki, ... Oncology 87 (6), 330-341, 2014 | 186 | 2014 |
| Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment F Piscaglia, S Ogasawara Liver cancer 7 (1), 104-119, 2018 | 132 | 2018 |
| Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells T Saito, T Chiba, K Yuki, Y Zen, M Oshima, S Koide, T Motoyama, ... PloS one 8 (7), e70010, 2013 | 100 | 2013 |
| Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma T Chiba, T Saito, K Yuki, Y Zen, S Koide, N Kanogawa, T Motoyama, ... International journal of cancer 136 (2), 289-298, 2015 | 94 | 2015 |
| Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and-independent manners T Chiba, E Suzuki, K Yuki, Y Zen, M Oshima, S Miyagi, A Saraya, S Koide, ... PloS one 9 (1), e84807, 2014 | 89 | 2014 |
| Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma S Ogasawara, T Chiba, Y Ooka, E Suzuki, N Kanogawa, T Saito, ... Investigational new drugs 33, 1257-1262, 2015 | 87 | 2015 |
| Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors S Ogasawara, T Chiba, Y Ooka, N Kanogawa, T Saito, T Motoyama, ... Investigational New Drugs 33, 729-739, 2015 | 84 | 2015 |
| Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma K Ueshima, S Ogasawara, M Ikeda, Y Yasui, T Terashima, T Yamashita, ... Liver Cancer 9 (5), 583-595, 2020 | 82 | 2020 |
| A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization S Ogasawara, T Chiba, Y Ooka, N Kanogawa, T Motoyama, E Suzuki, ... Hepatology 67 (2), 575-585, 2018 | 72 | 2018 |
| Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan S Ogasawara, Y Ooka, N Itokawa, M Inoue, S Okabe, A Seki, Y Haga, ... Investigational New Drugs 38, 172-180, 2020 | 71 | 2020 |
| Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma S Maruta, S Ogasawara, Y Ooka, M Obu, M Inoue, N Itokawa, Y Haga, ... Liver Cancer 9 (4), 382-396, 2020 | 67 | 2020 |
Akinobu TawadaChiba University Clinical OncologyVerified email at chiba-u.jp
